Five takeaways on progress altering the Parkinson’s therapeutic landscape, from day two of The Michael J. Fox Foundation’s ...

Each year, The Michael J. Fox Foundation (MJFF) hosts the Parkinson’s Disease Therapeutics Conference (PDTC), the world’s only scientific meeting devoted exclusively to Parkinson’s drug development.

We’re thrilled to be back for another year at Carson Beach! Whether you walk, run, volunteer, or cheer from the sidelines, your participation helps fuel progress and brings us closer to a cure.

The Michael J. Fox Foundation for Parkinson’s Research invites you to our free educational event for people with Parkinson’s and their loved ones. Join us in Washington, D.C. on October 24, 2026 at ...

This small event features an interactive program with remarks on the state of Parkinson’s research and progress toward a cure. You’ll learn about our landmark Parkinson’s Progression Markers ...

Donna Krenicki believes in momentum. Whether she’s hiking, golfing or spending the day with her young grandchildren (five under the age of 5), movement has always been central to her life. It’s how ...

The U.S. Food and Drug Administration has approved a treatment that uses focused ultrasound on both sides of the brain (in two procedures, months apart) for the management of Parkinson’s-related ...

As part of The Michael J. Fox Foundation’s goal to support the development of new and better Parkinson’s treatments, we are regularly assessing and tracking the drug development pipeline. Five areas ...

The U.S. Department of Veterans Affairs (VA) recently announced they will put into effect legislation to provide health care and benefits for veterans who served in the military in Southwest Asia with ...

Editor’s note (March 21, 2024): This blog describes a skin test that detects the biology of Parkinson’s and related diseases, and, as such, is a valuable research tool. On March 20, 2024, researchers ...

The U.S. Food and Drug Administration (FDA) has approved tavapadon, a once-daily oral medication for the treatment of motor symptoms of Parkinson’s disease. Tavapadon, which will be sold under the ...

The U.S. Food and Drug Administration (FDA) has approved a new, long-acting oral formulation for the treatment of Parkinson's disease. Developed by Amneal Pharmaceuticals, Crexont aims to offer ...